ARX-517 (JNJ-95298177): A Next-Generation PSMA-Targeted Antibody-Drug Conjugate for Advanced Prostate Cancer

1. Introduction

ARX-517, now designated JNJ-95298177 following corporate acquisition, represents an investigational, next-generation antibody-drug conjugate (ADC) engineered to target the prostate-specific membrane antigen (PSMA).[1] Developed initially by Ambrx Biopharma utilizing a proprietary expanded genetic code technology platform for precise, site-specific conjugation, ARX-517 embodies a novel approach to treating advanced prostate cancer.[1] The subsequent acquisition of Ambrx by Johnson & Johnson (J&J) in early 2024 underscores the perceived potential of this technology and the ARX-517 program specifically.[3]

The therapeutic rationale for ARX-517 is firmly rooted in the biology of prostate cancer and the validated role of PSMA as a therapeutic target. PSMA, a type II transmembrane glycoprotein, exhibits significantly elevated expression on the surface of prostate cancer cells, particularly in the context of metastatic castration-resistant prostate cancer (mCRPC), while displaying limited expression in most healthy tissues.[1] This differential expression profile makes PSMA an attractive target for directed therapies like ADCs. Furthermore, PSMA internalizes upon antibody binding, a crucial characteristic enabling the intracellular delivery of cytotoxic payloads conjugated to the targeting antibody.[14] The clinical validation of PSMA as a target was solidified by the approval and success of PSMA-targeted radioligand therapies, such as $^{177}$Lu-PSMA-617.[15] However, significant unmet medical need persists, particularly for patients with heavily pretreated mCRPC who have exhausted standard-of-care options, including potent androgen receptor pathway inhibitors (ARPIs) like abiraterone and enzalutamide, and taxane-based chemotherapy.[1] This patient population often faces a poor prognosis with limited survival.[3]

ARX-517 is positioned as a potential first- and best-in-class anti-PSMA ADC, distinguished by its design aimed at overcoming the limitations encountered by earlier generations of PSMA-targeted ADCs.[1] Historical challenges with ADCs targeting PSMA often involved issues of instability, leading to premature release of the cytotoxic payload in circulation and consequent off-target toxicities, which narrowed the therapeutic window and sometimes led to discontinuation of development.[7] ARX-517's engineering, featuring site-specific conjugation via non-natural amino acids and a highly stable, non-cleavable linker system, is intended to mitigate these issues, enhance the ADC's stability, reduce systemic toxicity, and thereby widen the therapeutic index.[1]

The strong external validation provided by J&J's $2 billion acquisition of Ambrx signals significant confidence in the underlying technology platform and the clinical potential of ARX-517.[3] This corporate commitment is expected to accelerate the ongoing clinical development program. Currently, ARX-517 is being evaluated in the APEX-01 (NCT04662580) clinical trial, a Phase 1/2 study investigating its safety, pharmacokinetics, and efficacy in patients with advanced prostate cancer.[2] Reflecting its potential to address an unmet need in a serious condition, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to ARX-517 for the treatment of mCRPC in July 2023.[1]

2. ARX-517: Design and Mechanism of Action

The therapeutic strategy embodied by ARX-517 integrates the targeting specificity of a monoclonal antibody with the potent cell-killing capability of a cytotoxic payload, delivered via a sophisticated conjugation technology designed for optimal stability and precision.

2.1 Targeting PSMA in Prostate Cancer

As previously noted, PSMA serves as an excellent target for ADC development in prostate cancer due to its high expression levels on malignant cells, particularly in advanced mCRPC, and its relatively low expression in normal tissues.[1] The protein's ability to internalize upon antibody binding is critical for the ADC mechanism, allowing the conjugate to be drawn into the cell where the payload can be released to exert its cytotoxic effect.[14] While PSMA expression is a prerequisite for the intended mechanism, the ongoing APEX-01 trial initially enrolled patients without mandatory baseline PSMA PET imaging selection, although PSMA expression is being evaluated as an exploratory biomarker.[8] This approach allows for assessment of ARX-517 activity across a broader, potentially more representative mCRPC population, while correlative studies may later define the relationship between expression levels and response.

2.2 Antibody Component

The targeting moiety of ARX-517 is a fully humanized monoclonal antibody (mAb) of the IgG1 kappa isotype, specifically engineered to bind to PSMA.[1] One source suggests the antibody may be based on the J591 binder.[35] The humanized nature minimizes potential immunogenicity, while the IgG1 isotype typically supports immune effector functions, although the primary mechanism of action for ADCs relies on payload delivery.

2.3 Payload: Amberstatin-269 (AS269)

ARX-517 utilizes Amberstatin-269 (AS269) as its cytotoxic payload.[1] AS269 is a proprietary, highly potent microtubule inhibitor developed by Ambrx.[1] Microtubules are essential components of the cellular cytoskeleton, critical for maintaining cell structure, intracellular transport, and cell division (mitosis). By binding to tubulin, the protein subunit of microtubules, AS269 inhibits its polymerization.[4] This disruption of microtubule dynamics leads to cell cycle arrest, typically in the G2/M phase, and ultimately triggers apoptosis, or programmed cell death, in the targeted cancer cell.[4] The payload is released intracellularly as pAF-AS269, where pAF refers to para-acetylphenylalanine, the synthetic amino acid involved in conjugation.[1] While AS269 is described as potent, its precise origin or structural class relative to other microtubule inhibitors like auristatins (e.g., MMAE, MMAF) or maytansinoids (e.g., DM1) is proprietary, although one source refers to it as a modified MMAF.[37] Regardless of its specific classification, its high cytotoxicity necessitates the precision delivery afforded by the ADC platform.[2]

2.4 Site-Specific Conjugation and Stable Linker Technology

A key differentiating feature of ARX-517 is the technology used to attach the AS269 payload to the anti-PSMA antibody. Ambrx's proprietary platform utilizes an expanded genetic code to incorporate a synthetic amino acid (SAA), specifically para-acetylphenylalanine (pAF), at precisely defined locations within the antibody's structure during its production in standard cell lines.[1] The AS269 payload is then site-specifically conjugated to this SAA using highly stable oxime chemistry.[7] This precise engineering results in a highly homogenous ADC preparation with a consistent drug-to-antibody ratio (DAR) of 2.[6]

The linker connecting the payload to the antibody is described as non-cleavable and incorporates a polyethylene glycol (PEG) component.[1] Non-cleavable linkers are designed to release the payload only upon complete degradation of the antibody component within the lysosome of the target cell, minimizing the potential for payload release in the bloodstream or bystander killing of adjacent non-target cells.[15]

The combination of site-specific conjugation, stable oxime chemistry, a homogenous DAR of 2, and a non-cleavable linker is designed to confer exceptional stability to ARX-517 in circulation.[1] This stability is hypothesized to be the critical factor enabling improved tolerability compared to less stable ADCs, by minimizing premature payload release and associated off-target toxicity. The resulting ADC exhibits mAb-like biophysical properties, further contributing to its favorable profile.[1] The ability to deliver a potent payload like AS269 safely is intrinsically linked to the precision and stability of this conjugation platform. The relatively low DAR of 2, compared to some other ADCs which might have higher DARs, may also contribute to the observed tolerability, while relying on the high potency of the AS269 payload for efficacy.

2.5 Cellular Uptake, Payload Release, and Cytotoxicity Pathway

The mechanism of action unfolds in a sequence of steps following intravenous administration:

Target Binding: ARX-517 circulates in the bloodstream and selectively binds to PSMA expressed on the surface of prostate cancer cells.[4]
Internalization: Upon binding, the ADC-PSMA complex is internalized by the cancer cell through endocytosis.[4]
Lysosomal Trafficking and Payload Release: The internalized complex is trafficked to lysosomes, the cell's degradation machinery. Within the lysosome, the antibody component of the ADC is catabolized (broken down), releasing the cytotoxic payload, pAF-AS269.[1] The non-cleavable nature of the linker ensures payload release is primarily dependent on this lysosomal degradation process.[15]
Cytotoxicity: The released AS269 payload enters the cytoplasm and exerts its effect by binding to tubulin and inhibiting microtubule polymerization. This disruption of the microtubule network halts the cell cycle in the G2/M phase and ultimately induces apoptosis, leading to the death of the PSMA-expressing cancer cell.[4]

Due to the stable, non-cleavable linker design, ARX-517 is expected to have minimal off-target bystander activity, meaning the payload is less likely to diffuse out of the target cell and affect neighboring, potentially healthy, cells.[15] This contrasts with some ADCs employing cleavable linkers, where bystander effect can sometimes contribute to efficacy but also potentially to toxicity.

3. Preclinical Validation

Extensive preclinical studies were conducted to characterize ARX-517's activity, pharmacokinetics, stability, and safety profile before its advancement into human clinical trials.

3.1 In Vitro Potency and Selectivity

In laboratory cell culture experiments, ARX-517 demonstrated highly specific and potent cytotoxic activity against prostate cancer cell lines that express high levels of PSMA, with activity observed at sub-nanomolar concentrations.[13] Its selectivity was confirmed, as cytotoxicity was primarily induced in PSMA-expressing cells.[14]

3.2 In Vivo Efficacy in Xenograft Models

The anti-tumor activity of ARX-517 was evaluated in various mouse models bearing human prostate cancer xenografts, including both cell line-derived (CDX) and patient-derived (PDX) models. These studies consistently showed dose-dependent inhibition of tumor growth.[13] A critical finding from these preclinical efficacy studies was the demonstration of activity in models resistant to enzalutamide, a standard-of-care ARPI used in mCRPC.[6] For instance, in an enzalutamide-resistant model, ARX-517 administered weekly at 3 mg/kg for three weeks significantly inhibited tumor growth by 79%.[18] Another comparison showed ARX-517 at 1 mg/kg and 3 mg/kg reduced tumor volume by 37% and 79%, respectively, in a resistant model, compared to only 14% reduction with enzalutamide itself.[18] This preclinical evidence strongly suggested that ARX-517 operates via a mechanism independent of the androgen receptor signaling pathway and could be effective in patients whose disease has progressed despite treatment with ARPIs, providing a solid rationale for its clinical investigation in the mCRPC setting.

3.3 Pharmacokinetics and Stability Assessment

Pharmacokinetic studies in mice confirmed that ARX-517 exhibited a long terminal half-life and achieved high serum exposure levels.[13] While a specific half-life value for ARX-517 in mice isn't provided in the snippets, the data supported the potential for less frequent dosing regimens. These studies also corroborated the high serum stability anticipated from its molecular design, attributed to the stable oxime conjugation and non-cleavable linker.[13]

3.4 Non-Human Primate (NHP) Toxicology and Therapeutic Index

To assess safety before human trials, repeat-dose toxicokinetic studies were performed in non-human primates (cynomolgus monkeys), a relevant species due to cross-reactivity of the antibody.[13] These studies revealed that ARX-517 was well-tolerated at exposure levels significantly exceeding those found to be efficacious in the mouse xenograft models.[13] This favorable safety profile in NHPs, combined with the efficacy data from mouse models, indicated a potentially wide therapeutic index for ARX-517.[13] The positive preclinical safety findings, particularly the good tolerability in NHPs at supra-therapeutic exposures, proved to be reasonably predictive of the manageable safety profile subsequently observed in the early dose-escalation phases of the APEX-01 human trial. This consistency reinforces the hypothesis that the ADC's engineered stability successfully translates into improved tolerability by minimizing off-target payload exposure.

4. Clinical Development Program: The APEX-01 Study (NCT04662580)

Based on the compelling preclinical data, ARX-517 advanced into clinical development with the APEX-01 trial.

4.1 Trial Identity and Status

The APEX-01 study, identified by the ClinicalTrials.gov identifier NCT04662580, is the first-in-human (FIH) clinical trial evaluating ARX-517.[2] Its official title reflects its scope: "A Phase 1, Multicenter, Open-Label, Dose-Escalation, and Dose-Expansion Study to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of ARX517 as Monotherapy and in Combination With Androgen Receptor Pathway Inhibitors in Subjects With Metastatic Prostate Cancer".[31] Initially sponsored by Ambrx Biopharma Inc., sponsorship transitioned to Janssen Research & Development, LLC following the acquisition by J&J.[2] The study commenced enrollment in July 2021 [15] and is currently active and recruiting participants, with an estimated primary completion date in September 2026.[31]

4.2 Objectives

The primary objectives of the APEX-01 trial are to assess the safety and tolerability profile of ARX-517, administered both as a monotherapy and in combination with ARPIs, and to determine the Maximum Tolerated Dose (MTD) and/or the Recommended Phase 2 Dose (RP2D).[2] Key secondary objectives include characterizing the pharmacokinetics (PK) and pharmacodynamics (PDy) of ARX-517, and gathering preliminary evidence of its anti-tumor activity, primarily through measurements of PSA response and radiographic tumor assessment using RECIST v1.1 criteria.[2]

4.3 Study Design

APEX-01 is structured as a multicenter, open-label Phase 1/2 trial.[2] The study incorporates several parts:

Phase 1a Dose Escalation: This part employs a standard 3+3 (or i3+3) design to identify the MTD/RP2D of ARX-517 monotherapy.[15] Patients receive escalating doses of ARX-517, typically administered as an intravenous infusion every 3 weeks (Q3W), although alternative schedules (e.g., Q4W) may also be explored.[18] Dose levels tested have ranged from 0.32 mg/kg up to 3.4 mg/kg.[6]
Phase 1b Dose Expansion: Following determination of the MTD/RP2D, dose expansion cohorts are planned to further evaluate the safety, tolerability, and preliminary efficacy of ARX-517 at the selected dose(s) in specific patient populations.[15] These cohorts are expected to enroll approximately 20-30 patients each.[23] Expansion cohorts are planned for both monotherapy and combination therapy.[2]
Combination Therapy Arms: The study protocol includes arms evaluating ARX-517 in combination with standard ARPIs, specifically enzalutamide, apalutamide, and abiraterone acetate plus prednisone (AAP).[18] These arms allow for early assessment of the safety and potential efficacy of combination regimens. The inclusion of these combination arms early in Phase 1 development likely reflects a strategic intent to rapidly explore ARX-517's potential beyond late-line monotherapy, possibly in earlier mCRPC settings or even in metastatic castration-sensitive prostate cancer (mCSPC), aligning with the goal of accelerating development under J&J.[3]

4.4 Patient Population

The trial enrolls adult male patients with metastatic prostate adenocarcinoma.[31] Specific eligibility criteria vary slightly between cohorts:

mCRPC Cohorts: Patients must have confirmed mCRPC (serum testosterone ≤50 ng/dL while on androgen deprivation therapy or post-orchiectomy) and have experienced disease progression (by PSA or radiographic criteria per PCWG3) on or after standard therapies.[15] Enrollment targets a heavily pretreated population, requiring progression after at least two prior FDA-approved treatments for prostate cancer, including at least one second-generation ARPI (e.g., abiraterone, enzalutamide).[1] The population studied has indeed been heavily pretreated, with a reported median of 4 prior lines of therapy (maximum 13), and significant prior exposure to ARPIs (100%), taxanes (66%), and even PSMA-targeted radionuclide therapy (17%).[6] Targeting this population directly addresses a high unmet need and provides a stringent test for ARX-517's activity.
mCSPC Combination Cohorts: These cohorts enroll patients with high-volume metastatic disease.[31]
General Criteria: Adequate organ function (including blood counts) is required.[15] For some cohorts (alternative dosing, combination), evidence of at least one PSMA-positive lesion and no measurable PSMA-negative lesions is required.[31] Key exclusions include recent prior anti-cancer therapies within specified wash-out periods, symptomatic or untreated CNS metastases (stable treated CNS metastases allowed), significant ocular disease, pre-existing Grade ≥2 peripheral neuropathy, and conditions predisposing to seizure (for apalutamide combination).[30]

4.5 Enrollment and Locations

The target enrollment for the APEX-01 trial is approximately 253 participants.[31] As of September 2023, 65 patients had been enrolled in the dose-escalation phase.[21] Earlier reports indicated 22 patients dosed as of February 2023.[23] The trial is being conducted at multiple centers within the United States [1], including academic institutions like the University of California San Francisco (UCSF) and the University of California Los Angeles (UCLA).[31] At the time of the Fast Track Designation announcement in July 2023, APEX-01 was noted as the only ongoing clinical trial in the US evaluating a PSMA-targeted ADC.[1]

5. Clinical Efficacy Findings from APEX-01 (Monotherapy Dose Escalation)

Preliminary results from the monotherapy dose-escalation portion of the APEX-01 trial have demonstrated encouraging signs of anti-tumor activity in the heavily pretreated mCRPC patient population studied.[6]

5.1 Prostate-Specific Antigen (PSA) Response Rates

Significant reductions in PSA levels, a key biomarker in prostate cancer, were observed, particularly at higher dose levels of ARX-517, suggesting a dose-response relationship.[6]

Therapeutic Doses (≥2.0 mg/kg): Data presented with a September 5, 2023 cutoff, focusing on cohorts 6-8 (doses 2.0 mg/kg, 2.4 mg/kg, 2.88 mg/kg; n=23 evaluable patients), showed substantial PSA responses:
61% achieved a PSA reduction of ≥30% (PSA30).[23]
52% achieved a PSA reduction of ≥50% (PSA50).[6] This is a clinically meaningful endpoint often correlated with improved outcomes.
26% achieved a deep PSA reduction of ≥90% (PSA90).[23]
Dose Dependency: Comparison with lower dose cohorts reinforced the dose-response trend. For example, cohort 4 (1.4 mg/kg, n=16) reported a PSA50 rate of 25%, while cohort 6 (2.0 mg/kg, n=14 in an earlier analysis) showed a PSA50 rate of 50%.[6] An initial report from cohort 6 (n=3) showed even higher rates (100% PSA50, 67% PSA90), though based on very small numbers.[23]
Activity Post-PSMA TRT: Encouragingly, ARX-517 demonstrated activity even in patients who had previously received PSMA-targeted radionuclide therapy. Within the therapeutic dose range (2.0-2.88 mg/kg), 50% (3 out of 6) of patients with prior PSMA TRT exposure achieved a PSA50 response.[21] This finding suggests ARX-517 may overcome resistance mechanisms associated with PSMA radioligands or offer a distinct therapeutic approach within the PSMA-targeting landscape, potentially providing a valuable option for sequential therapy.
Rapidity of Response: PSA reductions were noted to occur rapidly, with examples of significant declines (91% and 33%) observed as early as 3 weeks after the first dose in patients receiving 3.4 mg/kg.[30]

5.2 Circulating Tumor DNA (ctDNA) Dynamics

Reductions in ctDNA levels, another measure of treatment response and tumor burden, were also observed, correlating with the PSA responses at therapeutic doses.

In evaluable patients from cohorts 6-8 (n=21), 81% achieved a ≥50% reduction in ctDNA levels.[6]
An earlier analysis of 5 evaluable patients in these cohorts showed a 100% rate of ≥50% ctDNA reduction.[28]

5.3 Radiographic Responses (RECIST v1.1)

Objective tumor responses based on imaging (RECIST v1.1 criteria) were also reported, although data were preliminary and based on a smaller number of evaluable patients with measurable disease at baseline (only 34% of the overall population had measurable lesions [26]).

Among 9 evaluable patients with measurable disease in cohorts 4-8, 5 (56%) showed target lesion reduction.[23]
Two confirmed partial responses (PRs) were observed within these cohorts.[23] One PR occurred in cohort 4 (1.4 mg/kg).[8]

The consistent positive signals across these diverse efficacy endpoints – PSA reduction, ctDNA clearance, and radiographic tumor shrinkage – particularly at doses ≥2.0 mg/kg, provide mutually reinforcing evidence of ARX-517's anti-tumor activity in this challenging, heavily pretreated mCRPC population. While preliminary, these results support the continued investigation and dose escalation of ARX-517.

Table 1: Summary of Preliminary Efficacy Results by Dose Cohort in APEX-01 (Monotherapy)

Dose Cohort (mg/kg Q3W)	Evaluable Patients (n) for PSA	PSA30 Rate (%)	PSA50 Rate (%)	PSA90 Rate (%)	Evaluable Patients (n) for ctDNA	ctDNA ≥50% Reduction Rate (%)	Evaluable Patients (n) for RECIST	RECIST ORR (%)
Cohorts 1-3 (0.32-1.07)	7 26	29 26	0 26	0 26	N/A	N/A	N/A	N/A
Cohort 4 (1.4)	16 26	38 26	25 6	6 26	N/A	N/A	Part of 9 evaluable in C4-8	See below
Cohort 5 (1.7)	5 26	40 26	0 26	0 26	N/A	N/A	Part of 9 evaluable in C4-8	See below
Cohorts 6-8 (2.0-2.88)	23 23	61 23	52 6	26 23	21 23	81 23	Part of 9 evaluable in C4-8	See below
Cohorts 4-8 Summary	N/A	N/A	N/A	N/A	N/A	N/A	9 23	22 (2 PR) 8
Cohort 9 (3.4)	2 (PSA secreting) 30	N/A	N/A	N/A	N/A	N/A	N/A	N/A

N/A: Data Not Available in provided snippets for this specific breakdown.

Note: Patient numbers and rates may vary slightly between different reports/data cuts.

6. Safety and Tolerability Profile of ARX-517

A key aspect of ARX-517's development is its potential to offer improved safety and tolerability compared to earlier PSMA-targeted ADCs, attributed largely to its enhanced stability.[6] Clinical data from the APEX-01 dose-escalation phase appear to support this hypothesis.

6.1 Overall Assessment

ARX-517 has been reported as generally well-tolerated across all dose levels tested, up to and including the 3.4 mg/kg Q3W dose level evaluated in cohort 9.[6] The safety profile is described as strong, favorable, and differentiated.[6]

6.2 Dose-Limiting Toxicities (DLTs)

Crucially, no DLTs were observed during the standard 21-day DLT assessment period for any of the dose escalation cohorts evaluated up to 3.4 mg/kg.[6] The absence of DLTs, even at doses demonstrating significant anti-tumor activity (≥2.0 mg/kg), is a highly positive signal in Phase 1 development and supports the premise of an improved therapeutic window compared to historical PSMA ADCs.

6.3 Serious Adverse Events (SAEs)

Consistent with the lack of DLTs, no treatment-related SAEs have been reported in patients receiving ARX-517 monotherapy in the APEX-01 dose escalation phase.[6] An initial report also noted no serious toxicities.[34]

6.4 Treatment-Related Adverse Events (TRAEs)

The overall incidence of TRAEs was manageable:

High-Grade TRAEs (Grade ≥3): No Grade 4 or 5 TRAEs were reported.[6] An early report indicated no Grade ≥3 TRAEs at all.[34] Later data cuts reported a low incidence of Grade 3 TRAEs: 9.2% (6/65) across all cohorts, and 13% (4/32) at the therapeutic dose range of 2.0-2.88 mg/kg.[6] These specific Grade 3 events were limited to lymphopenia (3 patients), transient platelet count decrease (2 patients), and one case of asymptomatic left ventricular dysfunction which was not deemed serious.[6]
Low-Grade TRAEs (Grade 1/2): The most frequently reported TRAEs were primarily Grade 1 or 2 in severity. Common events (≥10% incidence across all cohorts) included dry mouth (xerostomia, 24-28%), dry eye (22%), fatigue (20%), diarrhea (15%), decreased appetite (14%), nausea (14%), dysgeusia (altered taste, 12%), vomiting (12%), and increased aspartate aminotransferase (AST, 11%).[6] While requiring monitoring and potential supportive care, these events are generally considered manageable and contrast with the more severe toxicities (e.g., severe myelosuppression, neuropathy) sometimes associated with less stable ADCs or conventional chemotherapy.

6.5 Discontinuations

The rate of treatment discontinuation due to TRAEs was very low, reported at 3% (2 out of 65 patients).[6] This suggests that the adverse events experienced were generally manageable and did not necessitate stopping treatment for most patients.

The consistent safety findings across multiple data presentations, highlighting the absence of DLTs and treatment-related SAEs, alongside a low rate of Grade 3 TRAEs and manageable Grade 1/2 events, strongly support the assertion that ARX-517 possesses a favorable and potentially differentiated safety profile. This profile is intrinsically linked to the ADC's engineered stability, achieved through Ambrx's site-specific conjugation technology.

Table 2: Summary of Treatment-Related Adverse Events (TRAEs) in APEX-01 (Monotherapy Dose Escalation)

Adverse Event Category / Term	Any Grade Rate (%)	Grade ≥3 Rate (%)	Notes
Overall
Any TRAE	N/A	9.2 (6/65)	13% (4/32) at doses 2.0-2.88 mg/kg
Treatment-Related SAEs	0	0
Dose-Limiting Toxicities (DLTs)	0	0	Assessed during 21-day period per cohort
Discontinuations due to TRAEs	3 (2/65)	N/A
Common TRAEs (≥10% Any Grade)
Dry Mouth (Xerostomia)	24 - 28	0	Primarily Grade 1/2
Dry Eye	22	0	Primarily Grade 1/2
Fatigue	20	0	Primarily Grade 1/2
Diarrhea	15	0	Primarily Grade 1/2
Decreased Appetite	14	0	Primarily Grade 1/2
Nausea	14	0	Primarily Grade 1/2
Dysgeusia (Altered Taste)	12	0	Primarily Grade 1/2
Vomiting	12	0	Primarily Grade 1/2
Increased AST	11	N/A	Primarily Grade 1/2
Specific Grade 3 TRAEs Reported
Lymphopenia	N/A	~4.6 (3/65)	3 patients reported
Platelet Count Decrease	N/A	~3.1 (2/65)	2 patients reported; described as transient
Left Ventricular Dysfunction	N/A	~1.5 (1/65)	1 patient reported; described as asymptomatic and not deemed serious

N/A: Data Not Available or Not Applicable in provided snippets for this specific breakdown.

Note: Rates are approximate based on reported percentages and patient numbers.

7. Pharmacokinetics and Biomarker Analysis

Pharmacokinetic (PK) assessments and biomarker analyses from the APEX-01 trial provide further insights into ARX-517's behavior in humans and confirm key aspects of its design.

7.1 Clinical Pharmacokinetic Profile

PK analyses were conducted across the dose-escalation cohorts.[2] The results indicated dose-proportional exposure, meaning that as the dose increased, the amount of drug measured in the bloodstream increased predictably. A key finding was the determination of a long terminal half-life for ARX-517, reported as up to 10 days.[6] This extended half-life allows the drug to remain in circulation for a prolonged period, supporting the Q3W dosing interval used in the trial and potentially allowing for even less frequent administration. This sustained exposure is believed to enable consistent therapeutic pressure on PSMA-expressing tumor cells between doses.[6] The combination of a long half-life and the observed dose-dependent efficacy provides a strong pharmacokinetic basis for the dosing strategy and suggests that maintaining exposure above a critical threshold is important for clinical activity.

7.2 ADC Stability in Circulation

A critical finding from the clinical PK data was the direct validation of ARX-517's stability in human circulation.[6] Analyses revealed virtually overlapping concentration-time curves for the total anti-PSMA antibody and the intact ADC across all tested dose levels (0.32 to 2.4 mg/kg).[6] This overlap signifies that the vast majority of the antibody circulating in the blood remains conjugated to the payload, confirming minimal premature release of AS269.[6] It was noted that ARX-517 was the first anti-PSMA ADC to demonstrate such strong stability in circulation.[18] Furthermore, measurements of free AS269 payload in patient serum showed maximum concentrations below 1 nM, a level reported to be approximately 100 times lower than the concentration required to induce toxicity in normal cells in vitro.[6] This clinical PK evidence provides crucial in vivo human validation of the stability engineered into ARX-517 preclinically and offers a mechanistic explanation for the favorable safety profile observed, particularly the lack of severe systemic toxicities often associated with payload deconjugation.

7.3 Biomarker Findings

While the APEX-01 trial enrolled patients regardless of baseline PSMA expression levels, PSMA PET imaging was included as an exploratory assessment.[8] The relationship between PSMA expression levels and response to ARX-517 remains an area for further investigation based on these exploratory analyses. As noted previously, ctDNA dynamics showed promise as a potential biomarker of response, with high rates of ≥50% ctDNA reduction observed in patients treated at therapeutic doses.[6]

8. Regulatory Status and Future Outlook

ARX-517's development trajectory has been positively influenced by regulatory recognition and significant corporate investment.

8.1 FDA Fast Track Designation

In July 2023, the FDA granted Fast Track designation to ARX-517 for the treatment of mCRPC in patients whose disease progressed following treatment with an AR pathway inhibitor.[1] This designation is significant as it acknowledges the serious nature of mCRPC, the unmet medical need in this patient population, and the potential for ARX-517 to offer a substantial improvement over existing therapies.[1] Fast Track designation facilitates more frequent interactions with the FDA and makes the drug potentially eligible for accelerated approval and priority review pathways if relevant criteria are met, potentially shortening the time to market.[1]

8.2 Ongoing Development and Future Clinical Plans

The APEX-01 trial (NCT04662580) remains the cornerstone of ARX-517's clinical development. Dose escalation continued into late 2023, with cohort 9 evaluating 3.4 mg/kg Q3W.[6] The determination of the RP2D was anticipated in early 2024 [32], which would allow for the initiation of Phase 1b/2 dose expansion cohorts.[29] These expansion cohorts will further evaluate ARX-517 monotherapy and, importantly, the combination regimens with ARPIs (enzalutamide, apalutamide, abiraterone acetate + prednisone) in both mCRPC and potentially mCSPC populations.[18] The inclusion of these combination arms early in development signals a strategy to explore ARX-517's utility beyond late-line monotherapy, potentially positioning it in earlier treatment settings or leveraging synergistic effects. Johnson & Johnson has explicitly stated its intention to accelerate the APEX-01 study and advance the Ambrx pipeline following the acquisition.[3] J&J's current pipeline lists JNJ-8177 (ARX-517) in Phase 1 development for prostate cancer.[12] The combination of FDA Fast Track status and J&J's resources suggests a commitment to an expedited development pathway, contingent on continued positive clinical data.

8.3 Potential Role in mCRPC Treatment Landscape

Based on the promising preliminary data, ARX-517 holds potential as a significant addition to the treatment armamentarium for advanced prostate cancer, particularly mCRPC.[1] Its demonstrated activity in heavily pretreated patients, including those who have progressed on ARPIs, taxanes, and even PSMA-targeted radionuclide therapy, positions it to address a critical unmet need.[6] If ongoing trials confirm its efficacy and differentiated safety profile, ARX-517 could emerge as a first- or best-in-class anti-PSMA ADC.[1] Its mechanism, distinct from radioligand therapy, suggests it could offer a valuable alternative or sequential treatment option for patients suitable for PSMA-targeted approaches.[22] Further data from dose expansion and combination cohorts will be crucial in defining its ultimate role in the evolving mCRPC treatment paradigm.

9. Conclusion

ARX-517 (JNJ-95298177) is an investigational antibody-drug conjugate representing a sophisticated application of protein engineering to target PSMA-expressing prostate cancer cells. Its design incorporates a humanized anti-PSMA antibody, a potent microtubule inhibitor payload (AS269), and, critically, Ambrx's proprietary site-specific conjugation technology using synthetic amino acids and a stable, non-cleavable linker to achieve a homogenous DAR of 2.[1]

Preclinical studies provided a strong foundation, demonstrating potent and selective in vitro activity, in vivo efficacy in both enzalutamide-sensitive and -resistant prostate cancer models, and a favorable safety profile with a wide therapeutic index in non-human primates.[6]

Early clinical data from the ongoing Phase 1/2 APEX-01 trial (NCT04662580) in heavily pretreated mCRPC patients have been highly encouraging. ARX-517 monotherapy demonstrated dose-dependent anti-tumor activity, evidenced by significant PSA reductions (PSA50 rate of 52% at doses ≥2.0 mg/kg), substantial ctDNA clearance, and confirmed objective responses per RECIST v1.1.[6] Notably, activity was observed even in patients previously treated with PSMA-targeted radionuclide therapy.[21] Crucially, these efficacy signals were accompanied by a favorable safety and tolerability profile, with no DLTs or treatment-related SAEs reported in dose escalation up to 3.4 mg/kg, and only a low rate of Grade 3 TRAEs.[6] Clinical pharmacokinetic data confirmed the ADC's exceptional stability in circulation, providing a mechanistic basis for the observed safety profile.[6]

The granting of FDA Fast Track designation and the acquisition of Ambrx by Johnson & Johnson highlight the significant potential attributed to ARX-517.[1] Ongoing evaluation in the APEX-01 trial, including dose expansion and combination therapy cohorts, will be critical in further defining the efficacy, safety, and optimal use of ARX-517. Based on current evidence, ARX-517 (JNJ-95298177) stands as a promising, potentially first- or best-in-class PSMA-targeted ADC poised to address the significant unmet medical need for patients with advanced prostate cancer, particularly mCRPC.

Works cited

FDA Grants Fast Track Designation for Ambrx's ARX517 for ... - Ambrx, accessed April 30, 2025, https://ir.ambrx.com/news/news-details/2023/FDA-Grants-Fast-Track-Designation-for-Ambrxs-ARX517-for-the-Treatment-of-Metastatic-Castration-Resistant-Prostate-Cancer/default.aspx
Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer, accessed April 30, 2025, https://ir.ambrx.com/news/news-details/2023/Ambrx-Provides-Update-On-APEX-01-an-On-Going-Phase-1---2-Dose-Escalation-Study-Evaluating-ARX517-a-Proprietary-PSMA-Targeting-ADC-in-Metastatic-Castration-Resistant-Prostate-Cancer/default.aspx
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer, accessed April 30, 2025, https://www.jnj.com/media-center/press-releases/johnson-johnson-to-acquire-ambrx-advancing-next-generation-antibody-drug-conjugates-to-transform-the-treatment-of-cancer
Definition of anti-PSMA antibody-drug conjugate ARX517 - NCI ..., accessed April 30, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/anti-psma-antibody-drug-conjugate-arx517
ARX-517 Drug Profile - Ozmosi, accessed April 30, 2025, https://pryzm.ozmosi.com/product/20937
Ambrx Announces ARX517, a PSMA-Targeted ... - GlobeNewswire, accessed April 30, 2025, https://www.globenewswire.com/news-release/2023/10/23/2764675/0/en/Ambrx-Announces-ARX517-a-PSMA-Targeted-ADC-Demonstrates-a-Promising-52-PSA50-50-Reduction-and-a-Highly-Differentiated-Safety-and-PK-Profile-in-Patients-with-mCRPC-who-Progressed-on.html
Dr Shen on the Utility of ARX517 in mCRPC - OncLive, accessed April 30, 2025, https://www.onclive.com/view/dr-shen-on-the-utility-of-arx517-in-mcrpc
J&J deal cements Ambrx's transformation | ApexOnco - Oncology Pipeline, accessed April 30, 2025, https://www.oncologypipeline.com/apexonco/jj-deal-cements-ambrxs-transformation
Exploring the Latest ADC Deal by Ambrx Biopharma: A Guide to Rapidly Accessing Transaction Insights - Patsnap Synapse, accessed April 30, 2025, https://synapse.patsnap.com/blog/exploring-the-latest-adc-deal-by-ambrx-biopharma-a-guide-to-rapidly-accessing-transaction-insights
Johnson & Johnson to Acquire Synthetic Biology Company Ambrx for $2 Billion, accessed April 30, 2025, https://www.synbiobeta.com/read/johnson-johnson-to-acquire-synthetic-biology-company-ambrx-for-2-billion
ARX517-PSMA-ADC - ADC Review, Journal of Antibody-drug Conjugates, accessed April 30, 2025, https://www.adcreview.com/drugmap/arx517-psma-adc/
Development pipeline - investor.jnj.com, accessed April 30, 2025, https://www.investor.jnj.com/pipeline/development-pipeline/default.aspx
Preclinical characterization of ARX517, a next-generation anti ..., accessed April 30, 2025, https://aacrjournals.org/cancerres/article/83/7_Supplement/3997/724719/Abstract-3997-Preclinical-characterization-of
Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer - PMC, accessed April 30, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC11612621/
Abstract CT121: ARX517, an anti-PSMA ADC targeting mCRPC resistant or refractory to standard therapies: A phase 1 dose escalation and dose expansion study (ARX517-2011, NCT04662580) | Request PDF - ResearchGate, accessed April 30, 2025, https://www.researchgate.net/publication/370032344_Abstract_CT121_ARX517_an_anti-PSMA_ADC_targeting_mCRPC_resistant_or_refractory_to_standard_therapies_A_phase_1_dose_escalation_and_dose_expansion_study_ARX517-2011_NCT04662580
Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody-Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer - PubMed, accessed April 30, 2025, https://pubmed.ncbi.nlm.nih.gov/39172730/
Preclinical Characterization of ARX517, a Site-Specific Stable PSMA-Targeted Antibody–Drug Conjugate for the Treatment of Metastatic Castration-Resistant Prostate Cancer - AACR Journals, accessed April 30, 2025, https://aacrjournals.org/mct/article/23/12/1842/750247/Preclinical-Characterization-of-ARX517-a-Site
APEX-01 Looks to Add First PSMA-Directed ADC to Treatment Paradigm in mCRPC, accessed April 30, 2025, https://www.onclive.com/view/apex-01-looks-to-add-first-psma-directed-adc-to-treatment-paradigm-in-mcrpc
Pipeline | Ambrx, accessed April 30, 2025, https://ambrx.com/pipeline/
Johnson & Johnson Completes Acquisition of Ambrx » ADC Review, accessed April 30, 2025, https://www.adcreview.com/business-economics/johnson-johnson-completes-acquisition-of-ambrx/
Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatments, accessed April 30, 2025, https://ir.ambrx.com/news/news-details/2023/Ambrx-Announces-ARX517-a-PSMA-Targeted-ADC-Demonstrates-a-Promising-52-PSA50-50-Reduction-and-a-Highly-Differentiated-Safety-and-PK-Profile-in-Patients-with-mCRPC-who-Progressed-on-Multiple-FDA-Approved-Treatments/default.aspx
Emerging Data Behind 2 Antibody Drug Conjugates for Breast and Prostate Cancer, accessed April 30, 2025, https://www.targetedonc.com/view/emerging-data-behind-2-antibody-drug-conjugates-for-breast-and-prostate-cancer
ARX517 Monotherapy Achieves Early Efficacy in Heavily Pretreated ..., accessed April 30, 2025, https://www.targetedonc.com/view/arx517-monotherapy-achieves-early-efficacy-in-heavily-pretreated-mcrpc
Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (≥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatments - UroToday, accessed April 30, 2025, https://www.urotoday.com/conference-highlights/esmo-2023/esmo-2023-press-releases/147585-ambrx-announces-arx517-a-psma-targeted-adc-demonstrates-a-promising-52-psa50-50-reduction-and-a-highly-differentiated-safety-and-pk-profile-in-patients-with-mcrpc-who-progressed-on-multiple-fda-approved-treatments.html
ESMO 2023: APEX-01: First-in-Human Phase 1/2 Study of ARX517, an Anti-PSMA ADC, in Patients with mCRPC - UroToday, accessed April 30, 2025, https://www.urotoday.com/conference-highlights/esmo-2023/esmo-2023-prostate-cancer/147612-esmo-2023-apex-01-first-in-human-phase-1-2-study-of-arx517-an-anti-psma-adc-in-patients-with-mcrpc.html
ARX517 Demonstrates Early Efficacy With Favorable Safety in Heavily Pretreated mCRPC, accessed April 30, 2025, https://www.onclive.com/view/arx517-demonstrates-early-efficacy-with-favorable-safety-in-heavily-pretreated-mcrpc
Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress, accessed April 30, 2025, https://ir.ambrx.com/news/news-details/2023/Ambrx-Provides-Safety-and-Efficacy-Data-from-Ongoing-Phase-12-APEX-01-Trial-of-ARX517-in-mCRPC-at-ESMO-Congress/default.aspx
Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress - BioSpace, accessed April 30, 2025, https://www.biospace.com/ambrx-provides-safety-and-efficacy-data-from-ongoing-phase-1-2-apex-01-trial-of-arx517-in-mcrpc-at-esmo-congress
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer - LarvolClin, accessed April 30, 2025, https://clin.larvol.com/trial-detail/NCT04662580
ARX517 Shows Promising Safety and Efficacy in mCRPC - Targeted Oncology, accessed April 30, 2025, https://www.targetedonc.com/view/arx517-shows-promising-safety-and-efficacy-in-mcrpc
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in ..., accessed April 30, 2025, https://clinicaltrials.ucsf.edu/trial/NCT04662580
ARX517 demonstrates continued safety and efficacy in mCRPC - Urology Times, accessed April 30, 2025, https://www.urologytimes.com/view/arx517-demonstrates-continued-safety-and-efficacy-in-mcrpc
ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer - ClinicalTrials.Veeva, accessed April 30, 2025, https://ctv.veeva.com/study/arx517-in-subjects-with-metastatic-castration-resistant-prostate-cancer
FDA Awards Fast Track Designation to ARX517 for Metastatic Castration-Resistant Prostate Cancer - OncLive, accessed April 30, 2025, https://www.onclive.com/view/fda-awards-fast-track-designation-to-arx517-for-metastatic-castration-resistant-prostate-cancer
Antibody-Drug Conjugates in Prostate Cancer Treatment "Presentation" - John Lee, accessed April 30, 2025, https://www.urotoday.com/video-lectures/2025-ucsf-ucla-psma-conference/video/mediaitem/4754-antibody-drug-conjugates-in-prostate-cancer-treatment-presentation-john-lee.html
ARX788 - ADC Review, Journal of Antibody-drug Conjugates, accessed April 30, 2025, https://www.adcreview.com/arx788-her2-adc-drug-description/
ARX788, a Site-specific Anti-HER2 Antibody-Drug Conjugate, Demonstrates Potent and Selective Activity in HER2-low and T-DM1-resistant Breast and Gastric Cancers | Request PDF - ResearchGate, accessed April 30, 2025, https://www.researchgate.net/publication/342965402_ARX788_a_Site-specific_Anti-HER2_Antibody-Drug_Conjugate_Demonstrates_Potent_and_Selective_Activity_in_HER2-low_and_T-DM1-resistant_Breast_and_Gastric_Cancers

ARX-517 Advanced Drug Monograph

Generic Name